摘要
华法林是临床使用最广泛的口服抗凝药,其治疗窗窄,剂量个体差异大,容易发生出血或栓塞的风险。CYP2C9和VKORC1基因多态性明显影响华法林剂量。其他参与维生素摄入和循环,华法林转运的基因变异,以及microRNA也可能影响华法林剂量。该文结合国内外各种华法林稳定剂量预测模型研究,总结影响华法林剂量相关基因的最新研究进展,旨在为华法林个体化治疗提供参考和指导依据。
Warfarin is the most widely used oral anticoagulant with narrow therapeutic window, wide inter-individual variability and high risks of bleeding or thromboembolism. Polymorphisms in CYP2C9 and VKORC1 are the major determinants of warfarin dosage requirement. Other genetic factors involving in vitamin K intake and recycle, and warfarin transportation may influence warfarin stable maintenance dosage as well. microRNA might also play a role. Based on numerous warfarin stable dosage prediction algorithms studies, this review updates the studies of warfarin pharmacogenomics and its personalized treatment, with the aim of providing evidence for clinical practice.
出处
《中国药理学通报》
CAS
CSCD
北大核心
2013年第2期169-172,共4页
Chinese Pharmacological Bulletin
基金
国家高技术研究发展计划(863计划)(No2012AA02A518)
湖南省高校创新平台开放基金(No11K073)
